Insider Selling: Phreesia (NYSE:PHR) Insider Sells 2,059 Shares of Stock

Key Points

• Phreesia insider David Linetsky sold 2,059 shares at an average price of $22.36, representing a 1.18% decrease in ownership.
• The company's stock, Phreesia (NYSE:PHR), is currently priced at $23.11 and has a market capitalization of $1.38 billion.
• Several analysts have recently upgraded their price targets for Phreesia, with a consensus target of $33.85, indicating a moderate buy rating.

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider David Linetsky sold 2,059 shares of the company's stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $22.36, for a total value of $46,039.24. Following the completion of the sale, the insider owned 171,829 shares of the company's stock, valued at $3,842,096.44. This trade represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Linetsky also recently made the following trade(s):

• On Thursday, September 18th, David Linetsky sold 93 shares of Phreesia stock. The stock was sold at an average price of $23.94, for a total value of $2,226.42.
• On Wednesday, September 17th, David Linetsky sold 1,064 shares of Phreesia stock. The stock was sold at an average price of $23.50, for a total value of $25,004.00.
• On Tuesday, September 16th, David Linetsky sold 2,165 shares of Phreesia stock. The stock was sold at an average price of $23.28, for a total value of $50,401.20.
• On Friday, August 22nd, David Linetsky sold 17,445 shares of Phreesia stock. The stock was sold at an average price of $29.73, for a total value of $518,639.85.
• On Monday, August 18th, David Linetsky sold 78 shares of Phreesia stock. The stock was sold at an average price of $29.16, for a total value of $2,274.48.

Phreesia Price Performance

Shares of PHR traded up $0.17 during trading hours on Tuesday, hitting $23.11. 370,773 shares of the company were exchanged, compared to its average volume of 611,887. The company has a market capitalization of $1.38 billion, a PE ratio of -55.02 and a beta of 0.68. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. The firm has a fifty day simple moving average of $26.02 and a 200-day simple moving average of $25.99. Phreesia, Inc. has a one year low of $17.07 and a one year high of $32.76.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.08. The business had revenue of $117.26 million during the quarter, compared to analyst estimates of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The company's revenue was up 14.9% compared to the same quarter last year. During the same period last year, the company posted ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. As a group, sell-side analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on PHR shares. Needham & Company LLC boosted their target price on shares of Phreesia from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, September 5th. JMP Securities boosted their target price on shares of Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a research note on Monday, September 8th. Stephens reissued an "overweight" rating and set a $32.00 target price on shares of Phreesia in a research note on Wednesday, September 3rd. Truist Financial boosted their target price on shares of Phreesia from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Friday, September 5th. Finally, Piper Sandler boosted their target price on shares of Phreesia from $33.00 to $34.00 and gave the company an "overweight" rating in a research note on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $33.85.

Hedge Funds Weigh In On Phreesia

A number of hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. increased its stake in shares of Phreesia by 2.7% in the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company's stock worth $400,000 after acquiring an additional 375 shares during the last quarter. Diversified Trust Co increased its stake in shares of Phreesia by 1.0% in the second quarter. Diversified Trust Co now owns 45,042 shares of the company's stock worth $1,282,000 after acquiring an additional 426 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Phreesia by 2.8% in the second quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company's stock worth $569,000 after acquiring an additional 540 shares during the last quarter. Arcadia Investment Management Corp MI increased its stake in shares of Phreesia by 0.7% in the first quarter. Arcadia Investment Management Corp MI now owns 92,770 shares of the company's stock worth $2,371,000 after acquiring an additional 615 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. increased its stake in shares of Phreesia by 9.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company's stock worth $251,000 after acquiring an additional 792 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.